Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Transcept Pharmaceuticals Announces Expected FDA Extension Of Regulatory Review Period For Intermezzo(R)
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced that the U.S. Food and Drug Administration (FDA) has informed the company that it should expect to receive formal notice of a three month extension of the review period for the new drug application (NDA) for Intermezzo(R) (zolpidem tartrate sublingual tablet). The Intermezzo(R) NDA had been assigned a Prescription Drug User Fee Act (PDUFA) date of July 30, 2009. Under this revised timeline, Transcept now anticipates action from the FDA on the NDA on or before October 31, 2009.
generic viagra online
Faster, More Cost-effective DNA Test For Crime Scenes, Disease Diagnosis
Scientists in Japan are reporting development of a faster, less expensive version of the fabled polymerase chain reaction (PCR), a DNA test widely used in criminal investigations, disease diagnosis, biological research and other applications. The new method could lead to expanded use of PCR in medicine, the criminal justice system and elsewhere, the researchers say. Their study is scheduled for the July 15 issue of Analytical Chemistry, a semi-monthly journal.
News of the day
Liver Transplantation After Drug Induced Acute Liver Failure Examined By Study
Liver transplantation offers a good chance for survival for patients with drug induced acute liver failure, however, certain pre-transplant factors are associated with worse outcomes. Patients who are on life support, who have elevated serum creatinine, and children whose liver failure was caused by antiepileptic drugs did not fare as well after transplantation. These findings are in the July issue of Liver Transplantation, a journal published by John Wiley & Sons. The article is also available online at Wiley Interscience.
Cardiovascular

Regulating The Sugar Factory In Diabetes

Scientists in Sydney and Boston believe they may have identified a gene that controls abnormal production of sugar in the liver, a very troublesome problem for people with diabetes. The liver is the sugar factory for the body - when blood sugar (glucose) levels fall, the liver makes and releases more. In people with diabetes, especially Type 2 diabetes, the liver doesn"t stop making sugar when it should, so blood sugar levels can rise overnight while they sleep even though they haven"t eaten. Dr Jenny Gunton, diabetes specialist and endocrinologist from Sydney"s Garvan Institute of Medical Research, in collaboration with Dr Xiao Hui Wang and Professor Ronald Kahn from Harvard Medical School and Joslin Diabetes Centre in Boston, have published their findings in the journal Cell Metabolism, now online. "A lot of my patients will complain that they go to bed with a blood sugar of 5 and wake up with a blood sugar of 12," said Dr Gunton. "It upsets people when their blood sugar behaves as if they"re getting up in the night and having a really big snack. I have to tell them it"s just one of those unfair things about having diabetes." People with Type 2 diabetes do not produce enough insulin in the pancreas after a meal. At the same time, they are less able to use that insulin to move glucose into fat and muscle cells, a condition known as "insulin resistance". With her colleagues in Boston, Gunton has been studying a transcription factor, or kind of "master regulator", called ARNT, which controls expression of other genes involved in processes like glucose breakdown and insulin production. In an earlier study, the group showed that there is 90% less ARNT in insulin-producing cells of people with Type 2 diabetes. The current study looks at how ARNT might be affecting the liver, and its results confirmed Dr Gunton"s suspicions. "We"ve shown that there"s likely to be decreased ARNT in the liver of people with Type 2 diabetes compared to people without Type 2 diabetes," she said. "Working with mice, we found that glucose levels were elevated and there was glucose production from a "precursor", a not normally metabolised." Other results in the study show that to some extent ARNT is regulated by insulin, so that insulin resistance in itself will contribute to a decrease in ARNT. If liver cells are treated with insulin, there will be a small increase in ARNT protein. The insulin will also help move the ARNT into the nucleus of the cell, where it does its job as a master regulator. The paper concludes that a decline in ARNT isn"t limited to the beta cells of people with Type 2 diabetes. ARNT is also reduced in other important diabetes-related tissues like the liver. Dr Gunton believes that if a new drug could be developed to increase ARNT activity in the liver, then it may be possible to shut down abnormal sugar production and improve blood sugar control in people with diabetes. Garvan


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009